BCL2 and acute lymphoblastic leukemia: Remarkably, other researchers have discovered, through BH3 profiling, that ETP-ALL is Bcl-2 dependent and is very sensitive to in vitro, testing an ETP cell line (LOUCY) and in vivo treatment with ABT-199, a drug tolerated well in clinical trials [25].